RxDoctor Payments Data

Engida Alemu, MD

Infectious Disease · Yuma, AZNPI 1710916705

Payments from drug & device makers

$542in general payments, 2019–2025

Across 34 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$199
  • Gilead$103
  • Astellas Pharma US Inc$80
  • AbbVie$77
  • Viiv Healthcare Company$65
  • Insmed, Inc.$19

What the payments were for

  • Food & beverage$50192%
  • Education$428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck15$199
Gilead6$103
Astellas Pharma US Inc4$80
AbbVie(2 entities)5$77
Viiv Healthcare Company3$65
Insmed, Inc.1$19

How this compares

$542 in reported general payments places this provider in the 55th percentile of 146 infectious disease providers in Arizona.

See all infectious disease providers in Arizona

Medicare billing

Part B allowed, 2024
$345,685
Medicare patients
648
Services billed
3,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala148$616,207
TivicayDolutegravir Sodium27$63,908
JulucaDolutegravir/Rilpivirine19$63,462
DescovyEmtricitabine/Tenofov Alafenam27$59,019
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$50,929
PrezcobixDarunavir/Cobicistat19$48,323
IsentressRaltegravir Potassium12$22,983
PifeltroDoravirine12$22,936
ErtapenemErtapenem Sodium25$10,478
Ceftazidime25$4,816
Vancomycin Hcl42$4,495
Cefepime Hcl20$4,438
Cephalexin113$2,419
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav55$1,286
ValacyclovirValacyclovir Hcl14$1,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$103$726,155188 claims
Viiv Healthcare CompanyTivicay, Juluca$65$127,37046 claims
MerckIsentress, Pifeltro$199$45,92024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 146 infectious disease providers in Arizona.

Other infectious disease in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →